<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The IV administration of the potent sigma1-receptor ligand 4-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-1-(4-phenylbutyl)<z:chebi fb="0" ids="18049">piperidine</z:chebi> (PPBP) provides neuroprotection against focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We tested the hypothesis that prolonged, continuous administration of PPBP would provide further neuroprotection in a rat model of transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>Under controlled conditions of normoxia, normocarbia, and normothermia, <z:chebi fb="2" ids="5615">halothane</z:chebi>-anesthetized male Wistar rats were subjected to 2 h of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> by the intraluminal occlusion technique </plain></SENT>
<SENT sid="3" pm="."><plain>Sixty minutes after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, rats were randomly assigned to six treatment groups to receive a continuous IV infusion of PPBP (1 micromol  </plain></SENT>
<SENT sid="4" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="5" pm="."><plain>h(-1) for 1, 2, 3, or 4 days or saline for 1 or 4 days </plain></SENT>
<SENT sid="6" pm="."><plain>The infarction volume was assessed by triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TFC) staining on Day 4 after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in <z:hpo ids='HP_0000001'>all</z:hpo> rats </plain></SENT>
<SENT sid="7" pm="."><plain>The TTC-determined infarction volume of the ipsilateral cerebral cortex was smaller in rats treated with PPBP for 1 day (42+/-13 mm3; 10%+/-3% of ipsilateral hemisphere; P &lt; 0.05) (mean+/-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) compared with that in corresponding 1-day control rats (124+/-22 mm; 29%+/-5% of ipsilateral hemisphere; P &lt; 0.05) or 4-day control rats (112+/-10 mm; 26%+/-2% of ipsilateral hemisphere; P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Cortical infarction volumes in 2-, 3-, and 4-day PPBP-treated rats were not different compared with 1- and 4-day saline-treated controls </plain></SENT>
<SENT sid="9" pm="."><plain>These data demonstrate that the sigma1(-receptor ligand PPBP attenuates ischemic injury when administration is initiated 60 min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> but that prolonged continuous treatment with PPBP beyond 24 h provides no neuroprotection </plain></SENT>
<SENT sid="10" pm="."><plain>IMPLICATIONS: sigma-Ligands decrease infarction size in various animal models when given after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Prolonged treatment with a potent sigma-ligand is associated with loss of therapeutic efficacy for this compound </plain></SENT>
</text></document>